Latest News and Press Releases

Longeveron granted FDA Type C meeting ahead of Q3 2026 data readout of pivotal clinical trial for stem cell therapy in hypoplastic left heart syndrome.

On track for top-line trial results in the third quarter of 2026 from pivotal Phase 2b clinical trial ELPIS II. ELPIS II is evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare...

Dr. Joshua Hare, CSO and Exec Chairman interviewed on NPR's BioTech Nation, discussing potential breakthrough stem cell therapy for HLHS.

Longeveron BOD appoints Interim CEO and Executive Chairman of BOD. Board plans to conduct a national search to identify a permanent CEO.

Longeveron will present and host investor meetings at the H.C. Wainwright 27th Annual Global Investment Conference taking place September 8-10, 2025.

Full enrollment achieved for pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare pediatric disease and orphan-designated...

Than Powell appointed as Longeveron CBO to lead overall business strategy, Alzheimer's program partnering and HLHS program international strategy.

Longeveron® completes enrollment of pivotal Phase 2b clinical trial evaluating laromestrocel as a treatment for Hypoplastic Left Heart Syndrome (HLHS).

Longeveron selected as a Semi-Finalist Team and one of the Top 40 Teams receiving a $250,000 Milestone 1 Award in the XPRIZE Healthspan competition.

Longeveron announces Q1 2025 financial results & provides business update. Pivotal Phase 2 clinical trial achieves 95% enrollment. Expected full enroll Q2.